NV4 Stock Overview
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Cellectar Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.10 |
| 52 Week High | US$3.88 |
| 52 Week Low | US$1.24 |
| Beta | 0.94 |
| 1 Month Change | -9.36% |
| 3 Month Change | -1.90% |
| 1 Year Change | 142.19% |
| 3 Year Change | -71.82% |
| 5 Year Change | -85.09% |
| Change since IPO | -98.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| NV4 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 10.7% | 2.2% | -1.0% |
| 1Y | 142.2% | -22.2% | 2.2% |
Return vs Industry: NV4 exceeded the German Biotechs industry which returned -22.2% over the past year.
Return vs Market: NV4 exceeded the German Market which returned 2% over the past year.
Price Volatility
| NV4 volatility | |
|---|---|
| NV4 Average Weekly Movement | 8.7% |
| Biotechs Industry Average Movement | 5.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: NV4's share price has been volatile over the past 3 months.
Volatility Over Time: NV4's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 20 | Jim Caruso | www.cellectar.com |
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom’s macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin’s lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors.
Cellectar Biosciences, Inc. Fundamentals Summary
| NV4 fundamental statistics | |
|---|---|
| Market cap | €113.89m |
| Earnings (TTM) | -€35.28m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.2x
P/E RatioIs NV4 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NV4 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$37.98m |
| Earnings | -US$37.98m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.06 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did NV4 perform over the long term?
See historical performance and comparison